Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

SV Health Investors

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 323
Average round size
info
The average size of a deal this fund participated in
$22M
Portfolio companies 172
Rounds per year 10.42
Lead investments 51
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.47
Exits 76
Key employees 7
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Medical
  • Therapeutics
Summary

SV Health Investors appeared to be the VC, which was created in 1993. The main office of represented VC is situated in the Boston. The venture was found in North America in United States.

We can highlight the next thriving fund investment areas, such as Biopharma, Medical. Among the most popular portfolio startups of the fund, we may highlight EBR Systems, AcuFocus, Schweiger Dermatology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The overall number of key employees were 7.

When the investment is from SV Health Investors the average startup value is 10-50 millions dollars. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. Comparing to the other companies, this SV Health Investors performs on 12 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the SV Health Investors, startups are often financed by Split Rock Partners, Polaris Partners, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Split Rock Partners, Novartis Venture Fund, DeNovo Ventures. In the next rounds fund is usually obtained by OrbiMed, Novo Holdings, Clarus Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of SV Health Investors:
Typical Co-investors
SV Health Investors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after SV Health Investors:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Spectrawave

Biotechnology
Health Care
Health Diagnostics
Medical
Medical Device
Therapeutics
$50M11 Sep 2024 Massachusetts, United States

Spineology

Emergency Medicine
Health Care
Manufacturing
Medical
Medical Device
$25M06 Aug 2024 St. Paul Park, Minnesota, United States

Brixton Biosciences

Biotechnology
Information Technology
Life Science
$33M14 May 2024 Cambridge, Massachusetts, United States

Miach Orthopaedics

Biotechnology
Health Care
Manufacturing
Medical
Medical Device
Wellness
$20M02 Apr 2024 Boston, Massachusetts, United States

Transine Therapeutics

Biotechnology
Life Science
$5M28 Nov 2023 Cambridge, England, United Kingdom

Eyebiotech

Biotechnology
Medical
$65M14 Nov 2023 New York, New York, United States

Sitryx Therapeutics

Biotechnology
Health Care
Pharmaceutical
$39M27 Sep 2023 Oxford, England, United Kingdom

Therini Bio

Biotechnology
Health Care
Medical
$36M27 Apr 2023 San Francisco, California, United States

Pulmocide

Biotechnology
Drug Discovery
Health Care
Health Diagnostics
Medical
Medical Device
Pharmaceuticals
$52M06 Dec 2022 London, England, United Kingdom
News
Zerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions

– Zerigo Health announced a $43m Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer.
– The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital.
– This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
– Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.

TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases

– TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59m Series A financing.
– Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
– Investors include Eli Lilly and Company, SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
– TRexBio also announced the appointment of Johnston Erwin as Chief Executive Officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical Officer, as part of the company’s plan to accelerate growth.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent SV Health Investors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 323
Average round size 22M
Rounds per year 10.42
Peak activity year 2016
Lead investments 51
Follow on index 0.47
Exits 76
Group Appearance index 0.75

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Spectrawave

Biotechnology
Health Care
Health Diagnostics
Medical
Medical Device
Therapeutics
$50M11 Sep 2024 Massachusetts, United States

Spineology

Emergency Medicine
Health Care
Manufacturing
Medical
Medical Device
$25M06 Aug 2024 St. Paul Park, Minnesota, United States

Brixton Biosciences

Biotechnology
Information Technology
Life Science
$33M14 May 2024 Cambridge, Massachusetts, United States

Miach Orthopaedics

Biotechnology
Health Care
Manufacturing
Medical
Medical Device
Wellness
$20M02 Apr 2024 Boston, Massachusetts, United States

Transine Therapeutics

Biotechnology
Life Science
$5M28 Nov 2023 Cambridge, England, United Kingdom

Eyebiotech

Biotechnology
Medical
$65M14 Nov 2023 New York, New York, United States

Sitryx Therapeutics

Biotechnology
Health Care
Pharmaceutical
$39M27 Sep 2023 Oxford, England, United Kingdom

Therini Bio

Biotechnology
Health Care
Medical
$36M27 Apr 2023 San Francisco, California, United States

Pulmocide

Biotechnology
Drug Discovery
Health Care
Health Diagnostics
Medical
Medical Device
Pharmaceuticals
$52M06 Dec 2022 London, England, United Kingdom
Crunchbase icon

Content report

The following text will be sent to our editors: